Be sure to check our sister interview main ratings news website

Tissue Regenix significantly undervalued which should correct (VIDEO)

Tissue Regenix Group plc (LON:TRX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.

Martin reminds us of what the company does, summerises the key details from its trading update, talks though the implications of a strong sales performance, the key value added in the reserach report and thoughts on what will happen to the share price.

Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products.

Read the full article
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Tissue Regenix: Turning profitable and cash-generative

    6th April 2023

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products

    Hardman & Co

    Tissue Regenix: Operating leverage

    27th September 2022

    Tissue Regenix Group plc (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of regenerative medicine products for

    Hardman & Co

    Tissue Regenix: Strong 1H’22 sales suggest upside potential

    20th July 2022

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: On pathway to sustainability

    19th April 2022

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: Faster-than-anticipated recovery

    20th October 2021

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine

    Hardman & Co

    Tissue Regenix Poised for Growth (Analyst Interview)

    9th July 2021

    Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance,

    Hardman & Co

    Tissue Regenix: Poised for growth

    1st July 2021

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine

    Hardman & Co

    Tissue Regenix Group: Funded through to profitability

    8th October 2020

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products

    Hardman & Co

    Tissue Regenix Restructured to satisfy product demand

    6th February 2020

    Tissue Regenix Group (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Credit facilities expand cash runway to 2021

    24th June 2019

    Tissue Regenix (LON: TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Expanded GPO coverage secured

    10th April 2019

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix 2018 in review: foundations laid for osteobiologics

    17th December 2018

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).

    © 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.